Actively Recruiting
Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
Led by Tanta University · Updated on 2019-11-19
60
Participants Needed
1
Research Sites
526 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis
CONDITIONS
Official Title
Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with spontaneous bacterial peritonitis
You will not qualify if you...
- Secondary peritonitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sherief Abd-Elsalam
Tanta, Egypt
Actively Recruiting
Research Team
S
Sherief Abd-Elsalam, ass. prof.
CONTACT
S
sherief abd-elsalam, ass. prof.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here